Financials in USD. Standardized financial statements.
A compact view of how Integra LifeSciences Holdings Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B | $1.37B | $1.52B | $1.47B | $1.19B | $992.08M |
| Revenue Growth? | +1.5% | +4.5% | -1.0% | +1.0% | +12.4% | -9.6% | +3.1% | +23.9% | +19.8% | 0.0% |
| Cost of Revenue? | $790.01M | $728.47M | $656.84M | $587.36M | $597.81M | $520.83M | $564.68M | $571.50M | $435.51M | $349.09M |
| Gross Profit? | $845.23M | $882.06M | $884.74M | $970.31M | $944.64M | $851.03M | $952.88M | $900.95M | $752.73M | $642.99M |
| Gross Margin? | +51.7% | +54.8% | +57.4% | +62.3% | +61.2% | +62.0% | +62.8% | +61.2% | +63.3% | +64.8% |
| Operating Expenses? | $776.92M | $853.65M | $773.21M | $731.39M | $747.41M | $699.66M | $859.12M | $789.95M | $707.92M | $527.65M |
| Operating Income? | $68.32M | $28.41M | $111.53M | $238.92M | $197.23M | $151.37M | $93.76M | $111.00M | $44.80M | $115.34M |
| EBITDA? | -$326.20M | $193.29M | $255.96M | $384.60M | $366.33M | $267.93M | $223.52M | $241.04M | $135.23M | $231.73M |
| Income Before Tax | -$563.50M | -$18.24M | $81.07M | $213.89M | $214.68M | $93.52M | $60.10M | $57.40M | $11.38M | $90.41M |
| Income Tax Expense | -$47.03M | -$11.29M | $13.33M | $33.34M | $45.60M | -$40.37M | $9.90M | -$3.40M | -$53.36M | $15.84M |
| Net Income? | -$516.47M | -$6.94M | $67.74M | $180.55M | $169.07M | $133.89M | $50.20M | $60.80M | $64.74M | $74.56M |
| EPS? | $-6.73 | $-0.09 | $0.87 | $2.18 | $2.00 | $1.58 | $0.59 | $0.73 | $0.83 | $1.00 |
| Diluted EPS? | $-6.73 | $-0.09 | $0.84 | $2.16 | $1.98 | $1.57 | $0.58 | $0.72 | $0.82 | $0.94 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality